Stability, cutaneous delivery, and antioxidant potential of a lipoic acid and α-tocopherol codrug incorporated in microemulsions.
Loading...
Issue Date
2014-08
Authors
Thomas, Siji
Vieira, Camila S
Hass, Martha A
Lopes, Luciana B
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
The aim of this study was to assess the skin penetration, stability, and antioxidant effects of a α-tocopherol-lipoic acid codrug. To enhance penetration, we evaluated three microemulsions varying in water content and composition of the oil phase (isopropyl myristate with either monocaprylin or oleic acid). The codrug was incorporated at 1% (w/w). Codrug hydrolysis in the microemulsion increased with increases in time (up to 48 h) and formulation water content (10%-30%, w/w). Microemulsions increased the codrug delivery into viable layers of porcine ear skin by 2.9-7.8-fold compared with a control formulation (20% monocaprylin in isopropyl myristate) after 24 h. Penetration enhancement was influenced by the oil phase, with the formulation containing monocaprylin displaying the most pronounced effect. Antioxidant activity, assessed in skin bioequivalents using the thiobarbituric acid-reactive substances (TBARS) assay, demonstrated that TBARS levels decreased by 39% after treatment with the codrug-containing microemulsion compared with the unloaded formulation. In addition to the codrug, tocopherol (8.2 ± 0.6 μg/cm(2)) was detected in the viable bioequivalent tissues, suggesting that the codrug was partly hydrolyzed after 12 h. Taken together, these results support the potential of nanodispersed formulations containing a tocopherol-lipoic acid codrug to improve skin antioxidant activity.
Citation
Thomas S, Vieira CS, Hass MA, Lopes LB. Stability, cutaneous delivery, and antioxidant potential of a lipoic acid and α-tocopherol codrug incorporated in microemulsions. J Pharm Sci. 2014 Aug;103(8):2530-8. doi: 10.1002/jps.24053. Epub 2014 Jun 24. PMID: 24961388; PMCID: PMC4498395.
ACPHS Research Commons URI
Description
Grants
R15 AR060008/AR/NIAMS NIH HHS/United States , 1R15AR060008-01A1/AR/NIAMS NIH HHS/United States